Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
Krishna Aragam, Director of Cardiovascular Genomics at Cleveland Clinic, posted on LinkedIn:
“Why are dilated cardiomyopathy (DCM) and heart failure about twice as common in individuals of self-identified Black race?
This risk difference has long been recognized but not fully explained by traditional risk factors or social determinants.
Our new paper in Nature Genetics identifies a key contributor: **a common loss-of-function variant in the gene CD36, specific to individuals of African ancestry, that increases risk of DCM.**
In the VA Million Veteran Program, we found that:
• 1 in 6 of African ancestry carries one copy → ~33% higher DCM risk
• 1 in 100 of African ancestry carries two copies → ~3× higher risk
• Variant is virtually absent in other populations
This single CD36 variant explains 8% of DCM in African ancestry populations — a greater impact on DCM than diabetes or chronic kidney disease — and accounts for 20% of the excess DCM risk compared with European ancestry individuals.
Mechanistically, CD36 encodes the transporter responsible for moving long-chain fatty acids (the heart’s main fuel) into cardiomyocytes. We found that loss of CD36 impairs fuel uptake, mitochondrial energy production, and contractility — revealing a myocardial energetic pathway to heart failure.
The variant’s higher frequency likely reflects positive selection in sub-Saharan Africa, where CD36 deficiency may have conferred protection against severe malaria.
This represents a new paradigm linking ancestry, metabolism, and heart failure.
Grateful to an extraordinary team across institutions, especially Jennifer Huffman, Liam Gaziano, and Zeina Al Sayed for leading this work, and Patrick Ellinor, Jacob Joseph, and Yan Sun for key support.
And most importantly, to all Veterans in the U.S. Department of Veterans Affairs Million Veteran Program, without whom this discovery would not have been possible.
Looking forward to extending this work across Cleveland Clinic, Mass General Brigham, the Broad Institute of MIT and Harvard, and other collaborating institutions to better understand the biology, refine early risk prediction, and explore how insights into myocardial energetics may guide new strategies for heart failure prevention and therapy.”
Title: An African ancestry-specific nonsense variant in CD36 is associated with a higher risk of dilated cardiomyopathy
Authors: Jennifer E. Huffman, Liam Gaziano, Zeina R. Al Sayed, Renae L. Judy, Laura M. Raffield, Kiran J. Biddinger, Brian Charest, Anant Chopra, David Gagnon, Xiuqing Guo, Vera Koledova, Michael G. Levin, Yuan-I Min, James P. Pirruccello, Nosheen Reza, Richard Ruan, Shefali Setia Verma, Bharath Ambale Venkatesh, Anurag Verma, Jie Yao, John Jeffrey Carr, Juan P. Casas, Kelly Cho, Joao A. C. Lima, Wendy S. Post, Daniel J. Rader, Marylyn D. Ritchie, Amil Shah, Kent D. Taylor, James G. Terry, Stephen S. Rich, Christopher J. O’Donnell, Lawrence S. Phillips, Kathryn L. Lunetta, Jerome I. Rotter, Peter W. F. Wilson, J. Michael Gaziano, Scott M. Damrauer, Yan V. Sun, Patrick T. Ellinor, Jacob Joseph, Krishna G. Aragam
Read full paper here.
Stay informed with Hemostasis Today.
-
Jul 9, 2026, 14:12Omar Hajji: Seasonal Determinants of Mortality in Sepsis and Cardiogenic Shock
-
Jul 9, 2026, 13:54Hussein Yassine: Why Omega-3s May Fall Short in Preventing Alzheimer’s Disease
-
Jul 9, 2026, 13:16Olivier Mathieu: Innovating the Future of Hemostasis at ISTH 2026
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders
-
Jul 9, 2026, 12:16Fernanda Betti Solano: Could Iron Deficiency Be Affecting Your Sleep?
-
Jul 9, 2026, 12:08Andreas Calatzis: What is the Rationale for Collagen-Induced Platelet Aggregation Testing?
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?